Nurix Therapeutics Inc
NRIX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.77B
Close$
Share Statistics
| Market cap | $2.77 Billion |
|---|---|
| Enterprise Value | $2.77 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.05 |
| Beta | 1.82 |
| Outstanding Shares | 111,563,067 |
Return
| Return on Equity | 73.24% |
|---|---|
| Return on Assets | 55.06% |
| Return on Invested Capital | 65.35% |
Valuation & Multiples
| P/E Ratio | 10.1 |
|---|---|
| PEG | -1.37 |
| Price to Sales | 4.22 |
| Price to Book Ratio | 8.45 |
| Enterprise Value to Revenue | 3.95 |
| Enterprise Value to EBIT | 9.15 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
October 12, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
$24.35 M
Average shareholder expectationNext Earnings Call
Expected Date
January 27, 2027
EPS Estimate
$-0.46
Average shareholder expectationRevenue Estimate
$37.95 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 32.69% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.24%▼ 106.07% |
|---|---|
| Total Invested | $6.26M▼ 99.78% |
| Investors Holding | 18▼ 200.00% |
ESG Score
No data
About Nurix Therapeutics Inc
2,020 employeesNurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other ch...